Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Genome-wide association study and whole-genome sequencing identify a deletion in LRIT3 associated with canine congenital stationary night blindness.

Das RG, Becker D, Jagannathan V, Goldstein O, Santana E, Carlin K, Sudharsan R, Leeb T, Nishizawa Y, Kondo M, Aguirre GD, Miyadera K.

Sci Rep. 2019 Oct 2;9(1):14166. doi: 10.1038/s41598-019-50573-7.

2.

TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.

Udagawa H, Hasako S, Ohashi A, Fujioka R, Hakozaki Y, Shibuya M, Abe N, Komori T, Haruma T, Terasaka M, Fujita R, Hashimoto A, Funabashi K, Yasuda H, Miyadera K, Goto K, Costa DB, Kobayashi SS.

Mol Cancer Res. 2019 Aug 29. doi: 10.1158/1541-7786.MCR-19-0419. [Epub ahead of print]

PMID:
31467113
3.

TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X.

Ito K, Nishio M, Kato M, Murakami H, Aoyagi Y, Ohe Y, Okayama T, Hashimoto A, Ohsawa H, Tanaka G, Nonoshita K, Ito S, Matsuo K, Miyadera K.

Mol Cancer Ther. 2019 May;18(5):920-928. doi: 10.1158/1535-7163.MCT-18-0645. Epub 2019 Mar 14.

PMID:
30872380
4.

Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations.

Nishio M, Murakami H, Ohe Y, Hida T, Sakai H, Kasahara K, Imamura F, Baba T, Kubota K, Hosomi Y, Shimokawa T, Hayashi H, Miyadera K, Tamura T.

Invest New Drugs. 2019 Feb 21. doi: 10.1007/s10637-019-00732-4. [Epub ahead of print]

PMID:
30790152
5.

Author Correction: Variabilities in retinal function and structure in a canine model of cone-rod dystrophy associated with RPGRIP1 support multigenic etiology.

Das RG, Marinho FP, Iwabe S, Santana E, McDaid KS, Aguirre GD, Miyadera K.

Sci Rep. 2018 Aug 24;8(1):13058. doi: 10.1038/s41598-018-31337-1.

6.

TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations.

Hasako S, Terasaka M, Abe N, Uno T, Ohsawa H, Hashimoto A, Fujita R, Tanaka K, Okayama T, Wadhwa R, Miyadera K, Aoyagi Y, Yonekura K, Matsuo K.

Mol Cancer Ther. 2018 Aug;17(8):1648-1658. doi: 10.1158/1535-7163.MCT-17-1206. Epub 2018 May 10.

7.

Mapping of Canine Models of Inherited Retinal Diseases.

Miyadera K.

Adv Exp Med Biol. 2018;1074:257-264. doi: 10.1007/978-3-319-75402-4_31. Review.

PMID:
29721951
8.

Usefulness of BCOR gene mutation as a prognostic factor in acute myeloid leukemia with intermediate cytogenetic prognosis.

Terada K, Yamaguchi H, Ueki T, Usuki K, Kobayashi Y, Tajika K, Gomi S, Kurosawa S, Saito R, Furuta Y, Miyadera K, Tokura T, Marumo A, Omori I, Sakaguchi M, Fujiwara Y, Yui S, Ryotokuji T, Arai K, Kitano T, Wakita S, Fukuda T, Inokuchi K.

Genes Chromosomes Cancer. 2018 Aug;57(8):401-408. doi: 10.1002/gcc.22542.

PMID:
29663558
9.

Variabilities in retinal function and structure in a canine model of cone-rod dystrophy associated with RPGRIP1 support multigenic etiology.

Das RG, Marinho FP, Iwabe S, Santana E, McDaid KS, Aguirre GD, Miyadera K.

Sci Rep. 2017 Oct 9;7(1):12823. doi: 10.1038/s41598-017-13112-w. Erratum in: Sci Rep. 2018 Aug 24;8(1):13058.

10.

Full-length mutation search of the TP53 gene in acute myeloid leukemia has increased significance as a prognostic factor.

Terada K, Yamaguchi H, Ueki T, Usuki K, Kobayashi Y, Tajika K, Gomi S, Kurosawa S, Miyadera K, Tokura T, Omori I, Marumo A, Fujiwara Y, Yui S, Ryotokuji T, Osaki Y, Arai K, Kitano T, Kosaka F, Wakita S, Tamai H, Fukuda T, Inokuchi K.

Ann Hematol. 2018 Jan;97(1):51-61. doi: 10.1007/s00277-017-3143-2. Epub 2017 Oct 4.

PMID:
28980058
11.

Canine genome assembly correction facilitates identification of a MAP9 deletion as a potential age of onset modifier for RPGRIP1-associated canine retinal degeneration.

Forman OP, Hitti RJ, Boursnell M, Miyadera K, Sargan D, Mellersh C.

Mamm Genome. 2016 Jun;27(5-6):237-45. doi: 10.1007/s00335-016-9627-x. Epub 2016 Mar 26.

PMID:
27017229
12.

Canine CNGA3 Gene Mutations Provide Novel Insights into Human Achromatopsia-Associated Channelopathies and Treatment.

Tanaka N, Dutrow EV, Miyadera K, Delemotte L, MacDermaid CM, Reinstein SL, Crumley WR, Dixon CJ, Casal ML, Klein ML, Aguirre GD, Tanaka JC, Guziewicz KE.

PLoS One. 2015 Sep 25;10(9):e0138943. doi: 10.1371/journal.pone.0138943. eCollection 2015.

13.

A Naturally Occurring Canine Model of Autosomal Recessive Congenital Stationary Night Blindness.

Kondo M, Das G, Imai R, Santana E, Nakashita T, Imawaka M, Ueda K, Ohtsuka H, Sakai K, Aihara T, Kato K, Sugimoto M, Ueno S, Nishizawa Y, Aguirre GD, Miyadera K.

PLoS One. 2015 Sep 14;10(9):e0137072. doi: 10.1371/journal.pone.0137072. eCollection 2015.

14.

Inherited retinal diseases in dogs: advances in gene/mutation discovery.

Miyadera K.

Dobutsu Iden Ikushu Kenkyu. 2014;42(2):79-89.

15.

The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile.

Fujita H, Miyadera K, Kato M, Fujioka Y, Ochiiwa H, Huang J, Ito K, Aoyagi Y, Takenaka T, Suzuki T, Ito S, Hashimoto A, Suefuji T, Egami K, Kazuno H, Suda Y, Nishio K, Yonekura K.

Mol Cancer Ther. 2013 Dec;12(12):2685-96. doi: 10.1158/1535-7163.MCT-13-0459. Epub 2013 Oct 18.

16.

Multiple mechanisms contribute to leakiness of a frameshift mutation in canine cone-rod dystrophy.

Miyadera K, Brierley I, Aguirre-Hernández J, Mellersh CS, Sargan DR.

PLoS One. 2012;7(12):e51598. doi: 10.1371/journal.pone.0051598. Epub 2012 Dec 12.

17.

Investigating the inheritance of prolapsed nictitating membrane glands in a large canine pedigree.

Edelmann ML, Miyadera K, Iwabe S, Komáromy AM.

Vet Ophthalmol. 2013 Nov;16(6):416-22. doi: 10.1111/vop.12015. Epub 2012 Dec 13. Erratum in: Vet Ophthalmol. 2014 Mar;17(2):156.

18.

Exclusion of RPGRIP1 ins44 from primary causal association with early-onset cone-rod dystrophy in dogs.

Kuznetsova T, Iwabe S, Boesze-Battaglia K, Pearce-Kelling S, Chang-Min Y, McDaid K, Miyadera K, Komaromy A, Aguirre GD.

Invest Ophthalmol Vis Sci. 2012 Aug 15;53(9):5486-501. doi: 10.1167/iovs.12-10178.

19.

Genome-wide association study in RPGRIP1(-/-) dogs identifies a modifier locus that determines the onset of retinal degeneration.

Miyadera K, Kato K, Boursnell M, Mellersh CS, Sargan DR.

Mamm Genome. 2012 Feb;23(1-2):212-23. doi: 10.1007/s00335-011-9384-9. Epub 2011 Dec 23.

20.

Genetic and phenotypic variations of inherited retinal diseases in dogs: the power of within- and across-breed studies.

Miyadera K, Acland GM, Aguirre GD.

Mamm Genome. 2012 Feb;23(1-2):40-61. doi: 10.1007/s00335-011-9361-3. Epub 2011 Nov 8. Review.

21.

The role of thymidine phosphorylase in the induction of early growth response protein-1 and thrombospondin-1 by 5-fluorouracil in human cancer carcinoma cells.

Matsushita S, Ikeda R, Nishizawa Y, Che XF, Furukawa T, Miyadera K, Tabata S, Ushiyama M, Tajitsu Y, Yamamoto M, Takeda Y, Minami K, Mataki H, Kanzaki T, Yamada K, Kanekura T, Akiyama S.

Int J Oncol. 2010 May;36(5):1193-200.

PMID:
20372793
22.

Phenotypic variation and genotype-phenotype discordance in canine cone-rod dystrophy with an RPGRIP1 mutation.

Miyadera K, Kato K, Aguirre-Hernández J, Tokuriki T, Morimoto K, Busse C, Barnett K, Holmes N, Ogawa H, Sasaki N, Mellersh CS, Sargan DR.

Mol Vis. 2009 Nov 11;15:2287-305.

23.

Fully automated measuring equipment for aqueous boron and its application to online monitoring of industrial process effluents.

Ohyama S, Abe K, Ohsumi H, Kobayashi H, Miyazaki N, Miyadera K, Akasaka K.

Environ Sci Technol. 2009 Jun 1;43(11):4119-23.

PMID:
19569339
24.

Clinical and pathological aspects of hemophilia a in Japanese Brown cattle.

Moritomo Y, Shimojo K, Miyadera K, Khalaj M, Asano Y, Kunieda T, Ogawa H.

J Vet Med Sci. 2008 Mar;70(3):293-6.

25.

An insertion mutation of the bovine Fii gene is responsible for factor XI deficiency in Japanese black cattle.

Kunieda M, Tsuji T, Abbasi AR, Khalaj M, Ikeda M, Miyadera K, Ogawa H, Kunieda T.

Mamm Genome. 2005 May;16(5):383-9.

PMID:
16104386
26.

Preparation of anti-orotate phosphoribosyltransferase antibody and its application to immunochemical detection in human tumor cells.

Sakamoto K, Sugimoto Y, Miyadera K, Oka T, Fukushima M.

Int J Mol Med. 2005 Aug;16(2):245-9.

PMID:
16012756
27.

[Preparation of anti-OPRT antibody for immunochemical detection].

Sakamoto K, Sugimoto Y, Miyadera K, Oka T, Fukushima M.

Gan To Kagaku Ryoho. 2005 May;32(5):653-8. Japanese.

PMID:
15918566
28.

Targeted deletion of both thymidine phosphorylase and uridine phosphorylase and consequent disorders in mice.

Haraguchi M, Tsujimoto H, Fukushima M, Higuchi I, Kuribayashi H, Utsumi H, Nakayama A, Hashizume Y, Hirato J, Yoshida H, Hara H, Hamano S, Kawaguchi H, Furukawa T, Miyazono K, Ishikawa F, Toyoshima H, Kaname T, Komatsu M, Chen ZS, Gotanda T, Tachiwada T, Sumizawa T, Miyadera K, Osame M, Yoshida H, Noda T, Yamada Y, Akiyama S.

Mol Cell Biol. 2002 Jul;22(14):5212-21.

29.

gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.

Basaki Y, Chikahisa L, Aoyagi K, Miyadera K, Yonekura K, Hashimoto A, Okabe S, Wierzba K, Yamada Y.

Angiogenesis. 2001;4(3):163-73.

PMID:
11911014
30.

[Gamma-hydroxybutyric acid, a metabolite of UFT, shows anti-angiogenic activities and antitumor effect].

Basaki Y, Miyadera K, Yonekura K, Aoyagi K, Chikahisa L, Okabe S, Hashimoto A, Kitazato K.

Gan To Kagaku Ryoho. 2002 Jan;29(1):89-94. Japanese.

PMID:
11816484
31.

Substrate phage as a tool to identify novel substrate sequences of proteases.

Ohkubo S, Miyadera K, Sugimoto Y, Matsuo K, Wierzba K, Yamada Y.

Comb Chem High Throughput Screen. 2001 Nov;4(7):573-83.

PMID:
11562260
32.

UFT and its metabolites inhibit cancer-induced angiogenesis. Via a VEGF-related pathway.

Basaki Y, Aoyagi K, Chikahisa L, Miyadera K, Hashimoto A, Yonekura K, Okabe S, Shibata J, Wierzba K, Yamada Y.

Oncology (Williston Park). 2000 Oct;14(10 Suppl 9):68-71.

33.

The role of thymidine phosphorylase in the pathogenesis of allergic rhinitis.

Nishimoto K, Matsune S, Miyadera K, Takebayashi Y, Furukawa T, Sumizawa T, Akiyama SI, Kurono Y.

Acta Otolaryngol. 2000 Aug;120(5):644-8.

PMID:
11039877
34.

Suppression of metastasis by thymidine phosphorylase inhibitor.

Takao S, Akiyama SI, Nakajo A, Yoh H, Kitazono M, Natsugoe S, Miyadera K, Fukushima M, Yamada Y, Aikou T.

Cancer Res. 2000 Oct 1;60(19):5345-8.

35.

[Anti-angiogenic activities of UFT and its metabolites, GHB and GBL, in the dorsal air sac (DAS) model in mice].

Basaki Y, Yonekura K, Chikahisa L, Okabe S, Hashimoto A, Miyadera K, Aoyagi K, Yamada Y.

Gan To Kagaku Ryoho. 2000 Jan;27(1):93-8. Japanese.

PMID:
10660738
36.

Identification of substrate sequences for membrane type-1 matrix metalloproteinase using bacteriophage peptide display library.

Ohkubo S, Miyadera K, Sugimoto Y, Matsuo K, Wierzba K, Yamada Y.

Biochem Biophys Res Commun. 1999 Dec 20;266(2):308-13.

PMID:
10600499
37.

UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice.

Yonekura K, Basaki Y, Chikahisa L, Okabe S, Hashimoto A, Miyadera K, Wierzba K, Yamada Y.

Clin Cancer Res. 1999 Aug;5(8):2185-91.

38.

The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors.

Matsushita S, Nitanda T, Furukawa T, Sumizawa T, Tani A, Nishimoto K, Akiba S, Miyadera K, Fukushima M, Yamada Y, Yoshida H, Kanzaki T, Akiyama S.

Cancer Res. 1999 Apr 15;59(8):1911-6.

39.

Expression of thymidine phosphorylase and vascular endothelial cell growth factor in human head and neck squamous cell carcinoma and their different characteristics.

Fukuiwa T, Takebayashi Y, Akiba S, Matsuzaki T, Hanamure Y, Miyadera K, Yamada Y, Akiyama S.

Cancer. 1999 Feb 15;85(4):960-9.

PMID:
10091776
40.

Thymidine phosphorylase in human esophageal squamous cell carcinoma.

Takebayashi Y, Natsugoe S, Baba M, Akiba S, Fukumoto T, Miyadera K, Yamada Y, Takao S, Akiyama S, Aikou T.

Cancer. 1999 Jan 15;85(2):282-9.

PMID:
10023693
41.

Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase.

Kitazono M, Takebayashi Y, Ishitsuka K, Takao S, Tani A, Furukawa T, Miyadera K, Yamada Y, Aikou T, Akiyama S.

Biochem Biophys Res Commun. 1998 Dec 30;253(3):797-803.

PMID:
9918807
42.

The expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor is correlated to angiogenesis in breast cancer.

Yonenaga F, Takasaki T, Ohi Y, Sagara Y, Akiba S, Yoshinaka H, Aikou T, Miyadera K, Akiyama S, Yoshida H.

Pathol Int. 1998 Nov;48(11):850-6.

PMID:
9832053
43.

Expression of thymidine phosphorylase is associated with a poor prognosis in patients with ductal adenocarcinoma of the pancreas.

Takao S, Takebayashi Y, Che X, Shinchi H, Natsugoe S, Miyadera K, Yamada Y, Akiyama S, Aikou T.

Clin Cancer Res. 1998 Jul;4(7):1619-24.

44.

Expression of thymidine phosphorylase and angiogenesis in human ovarian tumor.

Iemura K, Takebayashi Y, Miyadera K, Yamada Y, Akiyama S, Nagata Y.

Oncol Rep. 1997 Nov-Dec;4(6):1181-5.

PMID:
21590218
45.

Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma.

Imazano Y, Takebayashi Y, Nishiyama K, Akiba S, Miyadera K, Yamada Y, Akiyama S, Ohi Y.

J Clin Oncol. 1997 Jul;15(7):2570-8.

PMID:
9215827
46.

Thymidine phosphorylase activity required for tumor angiogenesis and growth.

Nishimoto K, Miyadera K, Takebayashi Y, Fukuda K, Haraguchi M, Furukawa T, Yamada Y, Akiyama S.

Oncol Rep. 1997 Jan-Feb;4(1):55-8.

PMID:
21590011
47.

Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma.

Takebayashi Y, Akiyama S, Akiba S, Yamada K, Miyadera K, Sumizawa T, Yamada Y, Murata F, Aikou T.

J Natl Cancer Inst. 1996 Aug 21;88(16):1110-7.

PMID:
8757190
48.

The activity and expression of thymidine phosphorylase in human solid tumours.

Takebayashi Y, Yamada K, Miyadera K, Sumizawa T, Furukawa T, Kinoshita F, Aoki D, Okumura H, Yamada Y, Akiyama S, Aikou T.

Eur J Cancer. 1996 Jun;32A(7):1227-32.

PMID:
8758258
49.

Expression of thymidine phosphorylase in human gastric carcinoma.

Takebayashi Y, Miyadera K, Akiyama S, Hokita S, Yamada K, Akiba S, Yamada Y, Sumizawa T, Aikou T.

Jpn J Cancer Res. 1996 Mar;87(3):288-95.

50.

The correlation of thymidine phosphorylase activity with the expression of interleukin 1 alpha, interferon alpha and interferon gamma in human colorectal carcinoma.

Takebayashi Y, Yamada K, Ohmoto Y, Sameshima T, Miyadera K, Yamada Y, Akiyama S, Aikou T.

Cancer Lett. 1995 Aug 16;95(1-2):57-62.

PMID:
7656244

Supplemental Content

Loading ...
Support Center